Draft guideline on the development and manufacture of Synthetic Peptides
Submitted by Anonymous (not verified) on 18 October 2023 - 14:08
Draft guideline on the development and manufacture of Synthetic Peptides
EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens
Submitted by Anonymous (not verified) on 18 October 2023 - 13:19
EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens
European Medicines Agency mid-year report 2023 (January-June 2023)
Submitted by Anonymous (not verified) on 18 October 2023 - 12:56
European Medicines Agency mid-year report 2023 (January-June 2023)
List of European Union reference dates and frequency of submission of periodic safety update reports (PSURs)
Submitted by Anonymous (not verified) on 18 October 2023 - 12:31
List of European Union reference dates and frequency of submission of periodic safety update reports (PSURs)
Human medicines European public assessment report (EPAR): Armisarte (previously Pemetrexed Actavis), pemetrexed, Carcinoma, Non-Small-Cell Lung;Mesothelioma, Date of authorisation: 18/01/2016, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 17 October 2023 - 16:38
Human medicines European public assessment report (EPAR): Armisarte (previously Pemetrexed Actavis), pemetrexed, Carcinoma, Non-Small-Cell Lung;Mesothelioma, Date of authorisation: 18/01/2016, Revision: 14, Status: Authorised
Workshop on generating clinical evidence for treatment and prevention options for long-COVID and post-acute sequelae condition (PASC), Online, 13:00 - 18:00 Amsterdam time (CET), from 17/11/2023 to 17/11/2023
Submitted by Anonymous (not verified) on 17 October 2023 - 16:18
Workshop on generating clinical evidence for treatment and prevention options for long-COVID and post-acute sequelae condition (PASC), Online, 13:00 - 18:00 Amsterdam time (CET), from 17/11/2023 to 17/11/2023
Lisdexamfetamine: List of nationally authorised medicinal products - PSUSA/00010289/202302
Submitted by Anonymous (not verified) on 17 October 2023 - 15:46
Lisdexamfetamine: List of nationally authorised medicinal products - PSUSA/00010289/202302
Trulicity (dulaglutide) supply shortage
Submitted by Anonymous (not verified) on 17 October 2023 - 15:28
Trulicity (dulaglutide) supply shortage
Human medicines European public assessment report (EPAR): Filsuvez, birch bark extract, Epidermolysis Bullosa Dystrophica;Epidermolysis Bullosa, Junctional, Date of authorisation: 21/06/2022, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 17 October 2023 - 11:30
Human medicines European public assessment report (EPAR): Filsuvez, birch bark extract, Epidermolysis Bullosa Dystrophica;Epidermolysis Bullosa, Junctional, Date of authorisation: 21/06/2022, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Xeplion, paliperidone, Schizophrenia, Date of authorisation: 04/03/2011, Revision: 16, Status: Authorised
Submitted by Anonymous (not verified) on 17 October 2023 - 10:15
Human medicines European public assessment report (EPAR): Xeplion, paliperidone, Schizophrenia, Date of authorisation: 04/03/2011, Revision: 16, Status: Authorised